VRTX Q4 2024 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.9B+15.7% YoY

Gross Profit

$2.5B85.5% margin

Operating Income

$1.0B35.2% margin

Net Income

$913M31.4% margin

EPS (Diluted)

$3.50

QoQ Revenue Growth

+5.1%

Cash Flow

Operating Cash Flow

$585M

Free Cash Flow

$492M

Stock-Based Comp.

$168M

Balance Sheet

Total Assets

$22.5B

Total Liabilities

$6.1B

Stockholders' Equity

$16.4B

Cash & Equivalents

$4.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.9B	$2.5B	+15.7%
Gross Profit	$2.5B	$2.1B	+15.8%
Operating Income	$1.0B	$989M	+3.8%
Net Income	$913M	$969M	-5.8%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.7B82%

Manufactured Product, Other

$595M18%

Geographic Segments

UNITED STATES

$1.8B63%

Europe

$832M29%

Other, Non U.S.

$243M8%